GCIPoolbeg Pharma to present POLB 001 pre-clinical data at 66th American Society of Hematology Annual Meeting
() , a clinical-stage biopharma company focused on infectious diseases, said it will present data related to its flagship POLB 001 anti-inflammatory candidate at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held from 7-19 December 2024 in San Diego, California.
Poolbeg's presentation will focus on POLB 001's potential to treat hyperinflammation associated with cytokine release syndrome (CRS) that affects patients receiving CAR T-cell cancer therapies. CRS is an often encountered side effect of such immunotherapies that causes potentially life-threatening hyperinflammation. CRS is also associated with severe influenza.
Specifically, Poolbeg will delve into positive results obtained from a pre-clinical POLB 001 in vivo study, a mouse model of immunotherapy-induced CRS.
Mark Sumeray MD, Consultant Clinical Advisor for Poolbeg, commenting: "These data underscore the potential for POLB 001 to prevent or reduce the severity of CRS. If this effect is demonstrated in the clinic, this would enable broader, safer delivery of cancer immunotherapies, including in an out-patient setting. We look forward to sharing these important findings with the global hematology community at ASH."
View from Vox
Poolbeg's second presentation at ASH represents further validation of POLB 001's potential in addressing CRS in oncology. The ASH Annual Meeting and Exposition is recognised as the world's premier conference focusing on hematological malignancies (blood cancers), bringing together 25,000 industry and academic attendees each year to share the latest advances in clinical care.
CRS is a well-recognised toxicity that occurs frequently following certain cancer treatments such as T-cell engaging antibodies and CAR T cell therapies. In addition to patient mortality and morbidity risk, the high frequency of CRS associated with these treatments represents a barrier to outpatient delivery. The need for in-patient management of CRS adds to the overall healthcare costs of delivering these treatments and contributes to restricting their availability.
An effective drug for CRS therefore has the potential to make cancer immunotherapies more tolerable and widely accessible, and enable patients to best benefit from their treatment. The positive results from the POLB 001 in vivo study further highlight the candidate's potential. Delivering an effective oral drug for CRS will be a significant value inflection point for Poolbeg.
The field of cancer immunotherapies is rapidly growing and expected to reach US$100bn by 2030. CRS is a significant obstacle to the delivery of lifesaving therapies, explaining the strong interest in POLB 001 from pharma companies seeking an effective and orally administrable solution to CRS. Poolbeg's second participation at ASH should benefit those discussions.
Follow News & Updates from Poolbeg Pharma:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.